Pharmacovigilance, Benefit-Risk Roadmap Topic of the ParagonRx Wednesday Webinar

WILMINGTON, Del.--(BUSINESS WIRE)-- In response to the explosion of regulatory guidances, many pharmaceutical companies have established new processes and structure for pharmacovigilance and benefit-risk management. However, the problem is that the training and competencies of those who have traditionally filled these roles may not be adequate to meet the new challenges.

This issue of core competencies and who will fulfill them will be addressed in a ParagonRx free webinar which will take place this Wednesday, November 10, at 12 noon Eastern Time.

Help Wanted: Qualified Pharmacovigilance Risk Management Professionals” is the latest in a series of monthly “Wednesday FoREMS” webinars sponsored by ParagonRx, an inVentiv Health, Inc. company and industry leading consults specializing in pharmaceutical risk management and optimizing medication.

“This is a classic issue of transformation,” says ParagonRx President Jeffrey Fetterman, “we know the destination, but now we need new skills, people and insights to get there. This webinar should be of interest to pharmaceutical executives who will be making pharmacovigilance and benefit-risk management decisions or are choosing the people who will be making those decisions.”

The webinar will be conducted by Mary Ellen Turner, MD, MPH, who has recently joined ParagonRx and who will share her insights based on deep pharmacovigilance experiences and her pioneering work in structuring risk management organizations. Dr. Turner will specifically answer the question, “Precisely, what does it take to be a successful Drug Safety/Risk Management professional and survive?” There will also be a Q&A session following the presentation.

More information about registering for the “Wednesday FoREMS” webinar series can be found at www.paragonrx.com/rems-hub/forems/. Webinars will be held the second Wednesday of each month at 12 noon EST.



CONTACT:

ParagonRx
Kevin Fetterman, (888) 459-8080 x236

KEYWORDS:   United States  North America  Delaware  Pennsylvania

INDUSTRY KEYWORDS:   Education  Continuing  Other Education  Health  Biotechnology  Medical Devices  Oncology  Pharmaceutical  FDA

MEDIA:

Logo
 Logo

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.